Evidence map›Paper›PMID 33098467›Full record

ArticleAnalytical and bioanalytical chemistry2021

Asymmetric flow field-flow fractionation coupled to surface plasmon resonance detection for analysis of therapeutic proteins in blood serum.

Mats Leeman, Willem M Albers, Radoslaw Bombera, Johana Kuncova-Kallio, Jussipekka Tuppurainen, Lars Nilsson

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mats LeemanSOLVE Research and Consultancy AB, Medicon village, 22381, Lund, Sweden.
Willem M AlbersBioNavis Ltd, Hermiankatu 6-8H, 337 20, Tampere, Finland.
Radoslaw BomberaBioNavis Ltd, Hermiankatu 6-8H, 337 20, Tampere, Finland.
Johana Kuncova-KallioBioNavis Ltd, Hermiankatu 6-8H, 337 20, Tampere, Finland.
Jussipekka TuppurainenBioNavis Ltd, Hermiankatu 6-8H, 337 20, Tampere, Finland.
Lars NilssonDepartment of Food Technology, Engineering and Nutrition, Faculty of Engineering LTH, Lund University, 22100, Lund, Sweden. lars.nilsson@food.lth.se.
Lund University · SEMedicon Village · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coupling of surface plasmon resonance (SPR) detection to asymmetric flow field-flow fractionation (AF4) offers the possibility to study active fractions of bio-separations on real samples, such as serum and saliva, including the assessment of activity of possibly aggregated species. The coupling of SPR with AF4 requires the possibility to select fractions from a fractogram and redirect them to the SPR. The combination of SPR with chromatography-like methods also requires a mechanism for regeneration of the receptor immobilised onto the SPR sensor surface. In recent work, the combination of size exclusion chromatography (SEC) with SPR was pioneered as a successful methodology for identification, characterisation and quantification of active biocomponents in biological samples. In this study, the approach using AF4 is evaluated for the antibody trastuzumab in buffer and serum. The particular object of this study was to test the feasibility of using AF4 in combination with SPR to detect and quantify proteins and aggregates in complex samples such as blood serum. Also, in the investigation, three different immobilisation methods for the receptor HER-2 were compared, which involved (1) direct binding via EDC/NHS, the standard approach; (2) immobilisation via NTA-Ni-Histag complexation; and (3) biotin/avidin-linked chemistry using a regenerable form of avidin. The highest specific activity was obtained for the biotin-avidin method, while the lowest specific activity was observed for the NTA-Ni-Histag linkage. The data show that AF4 can separate trastuzumab monomers and aggregates in blood serum and that SPR has the ability to selectively monitor the elution. This is an encouraging result for automated analysis of complex biological samples using AF4-SPR.

Indexed as

Antineoplastic Agents, ImmunologicalChromatography, GelErb-b2 Receptor Tyrosine KinasesFractionation, Field FlowHumansKineticsProtein BindingSurface Plasmon ResonanceTrastuzumabAntineoplastic Agents, ImmunologicalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabAggregateAntibodyAsymmetrical flow field-flow fractionationBinding capacityDetectionKineticsLigand immobilizationMulti-parametric surface plasmon resonance

Identifiers

PMID33098467
PMCPMC7801359
OpenAlexW3093630334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.